当类风湿性关节炎患者对肿瘤坏死因子抑制剂治疗无效时：下一步该怎么做？ - Suppr

Suppr

超能文献

When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

作者信息

Smolen Josef S, Weinblatt Michael E

出版信息

Ann Rheum Dis. 2008 Nov;67(11):1497-8. doi: 10.1136/ard.2008.098111.

DOI:10.1136/ard.2008.098111

PMID:18854512

Abstract

摘要

相似文献

When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step?

Ann Rheum Dis. 2008 Nov;67(11):1497-8. doi: 10.1136/ard.2008.098111.

Adalimumab for rheumatoid arthritis?

Am Fam Physician. 2006 Feb 1;73(3):435-6.

Rheumatoid arthritis.

N Engl J Med. 2004 Sep 23;351(13):1360-1; author reply 1360-1. doi: 10.1056/NEJM200409233511322.

New drugs for rheumatoid arthritis.

N Engl J Med. 2004 Aug 26;351(9):937-8. doi: 10.1056/NEJM200408263510922.

Development of type 1 diabetes mellitus in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor alpha.

Clin Exp Rheumatol. 2006 Sep-Oct;24(5):607.

Treatment of rheumatoid arthritis: we are getting there.

Lancet. 2009 Jul 18;374(9685):178-80. doi: 10.1016/S0140-6736(09)60792-3. Epub 2009 Jun 26.

Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial.

BMJ. 2015 Mar 13;350:h1046. doi: 10.1136/bmj.h1046.

Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis?

J Rheumatol. 2006 Feb;33(2):433; author reply 433-4.

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.

Lancet. 2009 Jul 18;374(9685):210-21. doi: 10.1016/S0140-6736(09)60506-7. Epub 2009 Jun 26.

Tofacitinib Versus Biologic Treatments in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Tumor Necrosis Factor Inhibitors: Results From a Network Meta-analysis.

Clin Ther. 2016 Dec;38(12):2628-2641.e5. doi: 10.1016/j.clinthera.2016.11.004. Epub 2016 Nov 24.

引用本文的文献

TNFα Receptor 1 and Not Receptor 2 Affect Annulus Fibrosus and Nucleus Pulposus Response to Cytokine Challenge in a Rat Model.

JOR Spine. 2025 May 19;8(2):e70070. doi: 10.1002/jsp2.70070. eCollection 2025 Jun.

Penfluridol targets acid sphingomyelinase to inhibit TNF signaling and is therapeutic against inflammatory autoimmune diseases.

Arthritis Res Ther. 2022 Jan 19;24(1):27. doi: 10.1186/s13075-021-02713-6.

Distinctive roles of tumor necrosis factor receptor type 1 and type 2 in a mouse disc degeneration model.

J Orthop Translat. 2021 Dec 3;31:62-72. doi: 10.1016/j.jot.2021.11.003. eCollection 2021 Nov.

Fexofenadine inhibits TNF signaling through targeting to cytosolic phospholipase A2 and is therapeutic against inflammatory arthritis.

Ann Rheum Dis. 2019 Nov;78(11):1524-1535. doi: 10.1136/annrheumdis-2019-215543. Epub 2019 Jul 13.

Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study.

Rheumatol Int. 2015 Sep;35(9):1525-34. doi: 10.1007/s00296-015-3237-x. Epub 2015 Mar 13.

Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis.

PLoS One. 2012;7(7):e40362. doi: 10.1371/journal.pone.0040362. Epub 2012 Jul 30.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7.

Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusion cycle: an open-label pharmacokinetic cohort study.

BMC Musculoskelet Disord. 2011 Jan 13;12:12. doi: 10.1186/1471-2474-12-12.

[Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].

Z Rheumatol. 2010 Sep;69(7):618-25. doi: 10.1007/s00393-009-0532-5.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs.

Ann Rheum Dis. 2010 Jun;69(6):964-75. doi: 10.1136/ard.2009.126532. Epub 2010 May 5.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验